Niraparib significantly improves outcomes for ovarian cancer patients

Share :
Published: 8 Oct 2016
Views: 2165
Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark

Dr Mirza speaks to ecancer at ESMO 2016 about results from the NOVA trial of niraparib, a PARP inhibitor, to treat platinum sensitive recurrent ovarian cancer.

Dr Mirza describes the significant extension of progression free survival in all patient subgroups assessed through the trial, hailing it as a 'break through'.

The results were published simultaneously to the conference in the New England Journal of Medicine.

Video of the press conference is available here.